We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-5.86%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$5.62B
AUM Growth
-$2.78B
Cap. Flow
-$2.47B
Cap. Flow %
-43.88%
Top 10 Hldgs %
56.27%
Holding
465
New
101
Increased
59
Reduced
84
Closed
204

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$44.1M
2
HRMY icon
Harmony Biosciences
HRMY
+$36.9M
3
TVTX icon
Travere Therapeutics
TVTX
+$33.9M
4
MDLN
Medline Inc
MDLN
+$22.4M
5
META icon
Meta Platforms (Facebook)
META
+$20.9M

Top Sells

Rank Stock Value
1
KVUE icon
Kenvue
KVUE
+$70.6M
2
IMVT icon
Immunovant
IMVT
+$56.5M
3
XRAY icon
Dentsply Sirona
XRAY
+$53.6M
4
GEHC icon
GE HealthCare
GEHC
+$53.1M
5
PTCT icon
PTC Therapeutics
PTCT
+$51.5M

Sector Composition

Rank Sector Weight
1 Healthcare 38.27%
2 Technology 7.29%
3 Consumer Discretionary 4.25%
4 Communication Services 1.58%
5 Consumer Staples 1.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$1.37B 24.28%
2,100,000
-900,000
-30% -$612M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$82.2B
$868M 15.43%
3,500,000
-4,600,000
-57% -$1.19B
TVTX icon
3
Travere Therapeutics
TVTX
$5.27B
$146M 2.59%
4,897,417
+1,133,526
+30% +$33.9M
PTCT icon
4
PTC Therapeutics
PTCT
$6.52B
$141M 2.51%
2,074,449
-727,420
-26% -$51.5M
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$12.8B
$139M 2.46%
264,583
-1,122
-0.4% -$536K
CYTK icon
6
CALL
Cytokinetics
CYTK
$10.9B
$112M 1.99%
1,700,000
+200,000
+13% +$12.7M
AGIO icon
7
CALL
Agios Pharmaceuticals
AGIO
$2.36B
$108M 1.93%
3,200,000
+200,000
+7% +$5.67M
SUPN icon
8
Supernus Pharmaceuticals
SUPN
$2.79B
$98M 1.74%
1,895,347
-868,653
-31% -$44.2M
NBIX icon
9
Neurocrine Biosciences
NBIX
$17.2B
$95.4M 1.7%
724,000
-96,240
-12% -$12.8M
AGIO icon
10
Agios Pharmaceuticals
AGIO
$2.36B
$91.9M 1.63%
2,716,000
-320,000
-11% -$9.07M
IMVT icon
11
Immunovant
IMVT
$8.27B
$88.6M 1.57%
3,564,916
-2,182,239
-38% -$56.5M
FRPT icon
12
Freshpet
FRPT
$2.78B
$64.5M 1.15%
1,093,307
-202,693
-16% -$14.2M
INCY icon
13
Incyte
INCY
$23.4B
$61.8M 1.1%
656,817
-441,285
-40% -$44M
DYN icon
14
Dyne Therapeutics
DYN
$3.92B
$57.6M 1.02%
3,175,110
-74,598
-2% -$1.29M
AMZN icon
15
Amazon
AMZN
$2.66T
$54.6M 0.97%
262,137
-105,496
-29% -$23.2M
IRWD icon
16
Ironwood Pharmaceuticals
IRWD
$635M
$52.7M 0.94%
15,028,000
-997,000
-6% -$4.09M
CYTK icon
17
Cytokinetics
CYTK
$10.9B
$50.4M 0.9%
764,538
-228,228
-23% -$14.5M
IMVT icon
18
CALL
Immunovant
IMVT
$8.27B
$47.2M 0.84%
1,900,000
+1,150,000
+153% +$29.8M
HRMY icon
19
Harmony Biosciences
HRMY
$1.96B
$45.5M 0.81%
1,624,000
+1,124,000
+225% +$36.9M
TMO icon
20
Thermo Fisher Scientific
TMO
$198B
$45M 0.8%
91,491
+28,653
+46% +$15.5M
NKTR icon
21
Nektar Therapeutics
NKTR
$2.31B
$41.6M 0.74%
578,000
-18,000
-3% -$1.02M
UNH icon
22
UnitedHealth
UNH
$387B
$40M 0.71%
+148,000
New +$44.1M
UBER icon
23
Uber
UBER
$147B
$37.3M 0.66%
518,760
+236,026
+83% +$18.2M
IMCR icon
24
Immunocore
IMCR
$1.78B
$35.8M 0.64%
1,188,000
+90,000
+8% +$2.91M
XRAY icon
25
Dentsply Sirona
XRAY
$2.81B
$34.8M 0.62%
3,000,000
-4,298,000
-59% -$53.6M
1
2 3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Armistice Capital held 465 positions worth $5.62B, down 33% from $8.4B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Armistice Capital withdrew a net $2.47B in Q1 2026, closing 204 positions and reducing 84 holdings. Its most notable exit was argenx, an estimated $48.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 33% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Armistice Capital opened a new position in UnitedHealth worth $40M.

  • Armistice Capital's largest Q1 2026 buy was UnitedHealth: 148,000 shares worth $40M.
  • Armistice Capital added most to Harmony Biosciences in Q1 2026, an estimated $36.9M increase.
  • Armistice Capital's biggest Q1 2026 reduction was Kenvue, cutting an estimated $70.6M.
  • Armistice Capital fully exited argenx in Q1 2026, selling an estimated $48.8M.
  • Armistice Capital's ten largest holdings make up 56% of its $5.62B portfolio in Q1 2026.
  • Armistice Capital opened 101 new positions and closed 204 in Q1 2026.
  • Armistice Capital's portfolio value fell 33% quarter-over-quarter to $5.62B.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.